Showing 511-520 of 618 results for "".
Eyes on the Road
https://modernod.com/mod-issues/2020-apr/eyes-on-the-road/39102/Motor vehicle accident rates increased among patients with glaucoma.Corneal Ectasia After Refractive Surgery
https://modernod.com/mod-issues/2020-mar/corneal-ectasia-after-refractive-surgery/39097/Use of multiple imaging modalities and sensible patient selection criteria can reduce the risk.Ushering in a New Treatment Paradigm for Glaucoma: Updates on Novel Therapeutics and Disease-Modifying Treatments
https://modernod.com/topics/glaucoma/ushering-in-a-new-treatment-paradigm-for-glaucoma-updates-on-novel-therapeutics-and-disease-modifying-treatments/38079/Then, Now, and Tomorrow: Evolving the Management of Diabetic Retinopathy and the Role of the Optometrist
https://modernod.com/mod-issues/supplements-inserts/then-now-and-tomorrow-evolving-the-management-of-diabetic-retinopathy-and-the-role-of-the-optometrist/37955/Consensus Panel Highlights: Pharmacotherapy for Presbyopia and Considerations for the Posterior Segment
https://modernod.com/programs/cme/Consensus-Panel-Highlights-Pharmacotherapy-for-Presbyopia-and-Considerations-for-the-Posterior-Segment/36580/This supplement summarizes a panel discussion among optometrists and retina specialists who convened to discuss the expanding armamentarium of presbyopia-correcting eye drops and establish a set of best practices regarding diagnostic testing, patient candidacy, and follow-up regimens.The Importance of Collaborative Care for Patients With Diabetic Retinopathy
https://modernod.com/topics/retina/the-importance-of-collaborative-care-for-patients-with-diabetic-retinopathy/38027/- EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrantshttps://modernod.com/news/eyepoint-pharmaceuticals-announces-proceeds-of-28-9-million-from-exercised-warrants/2479829/EyePoint Pharmaceuticals announced that the company has received proceeds of $28.9 million from the exercise of warrants by EW Healthcare Partners, Rosalind Advisors, and another accredited investor (Second Tranche Investors). “We are pleased to receive the continued support of EW Healthc
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Bio-Tissue Receives FDA Clearance to Proceed with Clinical Study Using Investigational New Drug TTBT01https://modernod.com/news/bio-tissue-receives-fda-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-ttbt01/2478924/Bio-Tissue announced that its parent company TissueTech had received clearance from the FDA to proceed with a phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) investigational new drug (IND) TTBT01. This clearance represents another milest
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a